Cognito Therapeutics Raises $105M Series C to Accelerate Alzheimer’s Therapy Launch

Event summary

  • Cognito Therapeutics closed a $105M oversubscribed Series C round led by Morningside Ventures, IAG Capital Partners, and Starbloom Capital.
  • The funding will support the advancement of Spectris™ toward pivotal data readout, regulatory submission, and commercial launch in 2027.
  • Spectris™ is an investigational, at-home neuroprotective therapy designed to preserve cognition in Alzheimer’s patients.
  • The HOPE pivotal study (NCT05637801) is fully enrolled, with top-line data expected later in 2026.

The big picture

Cognito Therapeutics’ $105M Series C funding underscores the growing investor confidence in non-invasive neuroprotective therapies for Alzheimer’s disease. The oversubscription highlights the strategic importance of Spectris™ as a potential first-of-its-kind at-home therapy, positioning Cognito at the forefront of a shift toward decentralized, patient-centric treatment models in neurodegenerative care. The funding will also support the company’s expansion into other indications, reflecting broader industry trends toward multi-indication platforms in neurotechnology.

What we're watching

Regulatory Approval
Whether the anticipated 2027 market entry for Spectris™ will align with the FDA’s review timeline and approval process.
Clinical Validation
The impact of the HOPE study’s top-line data on Spectris™’s regulatory submission and commercial viability.
Market Expansion
The pace at which Cognito Therapeutics can expand Spectris™ into additional neurodegenerative indications.

Related topics

Biotechnology